Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has launched orphan drug vandetanib, a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease, in the US.
Subscribe to our email newsletter
AstraZeneca is in talks with relevant authorities on a trade name and is currently referring to the treatment by its generic name, vandetanib.
AstraZeneca Specialty Care vice president Lisa Schoenberg said vandetanib is the only medicine specifically approved for patients with this rare form of cancer.